All Client References
The high quality of the consulting services provided by GAEU is confirmed by a long reference list of companies and institutions that have taken advantage of EU grants and other public subsidies to minimize risks involved in their projects and investments.
We have assisted European clients from different areas of industry to obtain funding to research and development projects (R&D projects), investments in new technologies, staff training projects, implementation of renewable energy sources and international business development.
Colzyx: €2.5M t
Colzyx has used GAEU for both the Phase 1 SME Instrument and the Phase 2 Accelerator – both applications were granted. We have found GAEU to be very professional, dedicated and skilled. In addition, the atmosphere in collaboration with GAEU has been characterized by openness and a strong commitment to creating the best possible project proposals. Colzyx was granted € 2,5 million from the Horizon 2020 EIC Accelerator Pilot Phase 2 programme.
Dr. Eskil Söderlind, CEO
Betagenon: €1.8M t
In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products. GAEU has taken the leading role in shaping strategies behind our proposal, which resulted in the total scoring of 14.64 out of 15 – an almost perfect proposal. Based on my experience in cooperating with GAEU, I strongly recommend them as Horizon 2020 advisors.
- Thomas Edlund Ph.D., Prof. Founder, Chief Executive Officer
Cellink: €2.5M
The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Cellink was granted € 2.5M from the SME Instrument HORIZON 2020, phase 2.
“Collaborating with GAEU has been great! The team is very responsive, knowledgable, and supportive. Their work and efforts will help us ensure long term success. A company to depend on.”
- Erik Gatenholm, CEO
CombiGene AB: €3.3M
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. CombiGene was granted €3.3 million from the SME Instrument HORIZON 2020, phase 2.
“GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience of the complex application procedure and the professional hands-on support that we got throughout the entire process were very valuable. I look forward to a continued cooperation with them in the future.”
- Jan Nilsson, CEO, CombiGene
SenzaGen: €2.4M
At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds. The grant we have received will be the perfect catalyst for this vision. We will use the funding to bring an innovative product to the market, with potential to become the cornerstone of our long-term competitiveness. For a small life science company, a grant covering 100 % of the project costs is of unparalleled value. We would like to thank GAEU for supporting us to secure this grant. We have received excellent guidance and advice in the application process. The team responsible for our proposal was easy to work with and very knowledgeable. GAEU is an excellent Horizon 2020 advisor and long term business partner.
- Anki Malmborg Hager CEO
Corline Biomedical: €2.3M
Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Coreline was granted € 2.3M from the SME Instrument HORIZON 2020, phase 2.
“This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded to a Swedish life science company within SME Instrument and it will allow us to fully fund our entire clinical study on Renaparin®. Apart from the purely practical and economic implications, it is also a great recognition of our project. It is really encouraging that the European Commission has recognized the potential in our project. With this grant, we will be able to create a platform from which we can accelerate Corline’s growth in kidney transplantation and new indications. GAEU Consulting has been our advisor throughout the entire application process and wrote our grant application. The outstanding application scoring received is proof to the quality of their service. I highly recommend GAEU as Horizon 2020 advisors for Life Science companies.”
- Henrik Nittmar, PhD CEO
Ilya pharma AB: €3.0M
Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for Proof of Concept in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins. Ilya Pharma was granted € 3M from the SME Instrument HORIZON 2020, phase 2.
“The cooperation with GAEU has been very successful with Ilya Pharma. GAEU’s consultants handled the process excellently. They possess eminent knowledge on how to break down a very complex project into smaller, logical activities, and on how the different parts are connected. It feels very good to have GAEU standing beside us in the process when we are to deliver this 18 months project”
- Evenlina Vågesjö, CEO, Ilya Pharma
Klaria AB: €2.0M
Klaria’s business concept is based on developing and commercialising innovative products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Klaria received € 2M from the SME Instrument HORIZON 2020, phase 2.
“Working with GAEU has provided the necessary structure and balance to our application. Their experience in emphasizing and bringing out the broader potential of our innovation and expressing that potential in clear text has been the most valuable part of our interaction. Navigation of the H2020 application process is complex, but with the help of GAEU, Klaria has been able to focus on bringing out key points in the broad potential of our innovation and critically, will aid in our presentation of our company in discussions with investors and shareholders outside of the context of H2020.”
- Dr. Scott Boyer, CEO, Klaria
Idogen: €2.9M
Idogen’s technology platform allows cells from the patient’s blood to be reprogrammed outside the body to dendritic cells with the capacity to specifically counteract adverse immune reactions. Idogen was granted € 2.9M from the SME Instrument HORIZON 2020, phase 2.
“We warmly recommend GAEU Consulting services to Life Science companies seeking professional advice within Horizon 2020 funding.”
- VD Lars Hedbys
Scandinavian Biopharma: €3.0M
Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests. Scandinavian Biopharma received € 3.0M from the SME Instrument HORIZON 2020, phase 2.
“The contribution from the EU Commission is a strong recognition of our research, which strives toward developing a globally unique ETEC vaccine. The EU grant will be used to accelerate the clinical development of the vaccine and to take a significant step towards commercialisation. GAEU Consulting has been responsible for our application. We are very satisfied with the quality of the work effort and commitment from the team in Kraków”
- Björn Sjöstrand, CEO, Scandinavian Biopharma
Targeted Immunotherapies: €2.7M
The company develops the Tailored Leukapheresis (TLA) immunotherapy for immune mediated inflammatory diseases (IMIDs), which has demonstrated proof-of-concept in a Phase I/II clinical trial on inflammatory bowel disease (IBD). TLA was granted € 2.7M from the SME Instrument HORIZON 2020, phase 2. GAEU helped structuring the project, limiting the scope and building business argumentation. We made a grand contribution to the successful process by preparing the client for the pitch deck and interview in Brussels. We also created the presentation needed.
Vitrolife: €348k
For an innovative project in stemcell media, the listed biotech company Vitrolife AB was granted € 348,000 from the popular Research & Grow programme.
GAEU helped us with the successful application. One of Vinnova’s examiners said it was the best application they had ever read.
- Stefan Blomsterberg, Director of Strategic Projects
Verigraft: €2.2M
Verigraft is active in the field of regenerative medicine by developing personalized human tissues for transplantation. VERIGRAFT was granted € 2.2M from the SME Instrument HORIZON 2020, phase 2.
“The SME Instrument funding represents an important element on our way to the next level of development and we are very proud to have been promoted to the SME Champions league. The VERIGRAFT team is very thankful for this reward of our rock-solid commitment and we are highly motivated to make this project a great success. This funding will facilitate our high ambitions to develop novel products that can help millions of patients with today incurable diseases.”
- Dr. Petter Björquist, CEO, VERIGRAFT
Gearwheel: €190k
“Gearwheel is working on the development and sale of interchangeable wheelchairs, which make it easier for muscularly fragile users to move their own wheelchair. We are still an R&D intensive company and therefore have a clear need for external financing. GAEU helped us with an R&D application that resulted in a contribution of nearly SEK 2 million from Vinnova, which was a very important piece of the puzzle to secure our financing until major commercial revenue is generated from our new product.”
- John-Edvard Stenstrand, CEO
Beactica: €50k
Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. Beactica was granted € 50k from the SME Instrument HORIZON 2020, phase 1. GAEU helped structuring the project and highlight the parts essential in order for the commission to see the potential of the project, even though it was at a very early stage in its development, and very venturous.
BiBBinstruments: €50k
BiBBInstruments AB offers innovative, disposable instruments under the brand name EndoDrill® for earlier and more accurate diagnosis in the most common forms of cancer. BiBBinstruments was granted € 50k from the SME Instrument HORIZON 2020, phase 1. GAEU helped structuring the project and highlight the parts essential in order for the commission to see the potential of the project, even though it was at a very early stage in its development, and very venturous.
Cytacoat: €50k
CytaCoat has developed a unique and stable antimicrobial coating that uses non-toxic, biocompatible organic compounds that strongly bind to the surface of the device through covalent bonding. Cytacoat has been granted EUR 50k from SME Instrument Phase 1. GAEU helped structuring the project and highlight the parts essential in order for the commission to see the potential of the project, even though it was at a very early stage in its development, and very venturous.